DeGruttola V - Search Results

1

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.

Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Marschner IC, et al. Among authors: degruttola v. J Infect Dis. 1998 Jan;177(1):40-7. doi: 10.1086/513823. J Infect Dis. 1998. PMID: 9419168 Clinical Trial.

2

Assessing and modeling heterosexual spread of the human immunodeficiency virus in the United States.

De Gruttola V, Mayer KH. De Gruttola V, et al. Rev Infect Dis. 1988 Jan-Feb;10(1):138-50. doi: 10.1093/clinids/10.1.138. Rev Infect Dis. 1988. PMID: 3353626

3

The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.

Jacobson MA, De Gruttola V, Reddy M, Arduino JM, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, et al. Jacobson MA, et al. AIDS. 1995 Jul;9(7):727-34. doi: 10.1097/00002030-199507000-00010. AIDS. 1995. PMID: 7546418 Clinical Trial.

4

Evaluating surrogate markers.

Hughes MD, DeGruttola V, Welles SL. Hughes MD, et al. Among authors: degruttola v. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S1-8. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552506 Review.

5

Modelling progression of CD4-lymphocyte count and its relationship to survival time.

De Gruttola V, Tu XM. De Gruttola V, et al. Biometrics. 1994 Dec;50(4):1003-14. Biometrics. 1994. PMID: 7786983

6

Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial.

Fiscus SA, DeGruttola V, Gupta P, Katzenstein DA, Meyer WA 3rd, LoFaro ML, Katzman M, Ragni MV, Reichelderfer PS, Coombs RW. Fiscus SA, et al. Among authors: degruttola v. J Infect Dis. 1995 Feb;171(2):305-11. doi: 10.1093/infdis/171.2.305. J Infect Dis. 1995. PMID: 7844365 Clinical Trial.

7

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.

D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. D'Aquila RT, et al. Among authors: degruttola v. Ann Intern Med. 1995 Mar 15;122(6):401-8. doi: 10.7326/0003-4819-122-6-199503150-00001. Ann Intern Med. 1995. PMID: 7856987 Clinical Trial.

8

Uses of CD4-lymphocyte count in AIDS treatment decisions.

De Gruttola V, Gelman R, Lagakos S. De Gruttola V, et al. Infect Agents Dis. 1993 Oct;2(5):304-13. Infect Agents Dis. 1993. PMID: 7909710 Review. No abstract available.

9

Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex.

De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. De Gruttola V, et al. J Acquir Immune Defic Syndr (1988). 1993 Apr;6(4):359-65. J Acquir Immune Defic Syndr (1988). 1993. PMID: 8095980 Clinical Trial.

10

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.

DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S, Hollinger FB, Fischl MA, Volberding P. DeGruttola V, et al. J Infect Dis. 1994 Apr;169(4):713-21. doi: 10.1093/infdis/169.4.713. J Infect Dis. 1994. PMID: 8133085 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

222 results

Search Page